Artiva Biotherapeutics Names 35-Year Pharma Veteran Elaine Sorg Ahead of AlloNK Data
Artiva Biotherapeutics appointed Elaine Sorg, a 35-year pharma veteran who led U.S. commercialization of HUMIRA and RINVOQ, to its board of directors. Her strategic guidance will support preparation of AlloNK rheumatoid arthritis clinical activity data and FDA engagement for a registrational trial.
1. Board Appointment
On February 19, 2026, Artiva Biotherapeutics appointed Elaine Sorg to its Board of Directors. Her selection marks an effort to strengthen governance as the company advances its lead AlloNK cell therapy toward registrational studies in rheumatoid arthritis.
2. Elaine Sorg's Background
Ms. Sorg brings over 35 years of commercial leadership at AbbVie and Eli Lilly, including roles as senior vice president of U.S. commercial operations and head of U.S. Immunology. She spearheaded the launches of HUMIRA, RINVOQ, and Skyrizi, driving market penetration and patient access strategies for major immunology products.
3. Strategic Impact on AlloNK Program
Elaine Sorg’s expertise in scaling biopharma companies will guide preparation of clinical activity data from AlloNK’s ongoing rheumatoid arthritis trial. Her strategic perspective is expected to support Artiva’s FDA engagement and long-term commercialization planning for its off-the-shelf NK cell therapy.